Masimo Taps Katie Szyman

Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...
Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.
Looking ahead to 2025, Masimo projects healthcare revenues to land between $1.5 billion and $1.53 billion. That would deliver ...
BTIG analyst Marie Thibault reiterated a Buy rating on Masimo (MASI – Research Report) today and set a price target of $178.00. The company’s ...